Bayer licenses female sexual dysfunction product for up to Can$330 million
This article was originally published in Scrip
Executive Summary
Bayer and EndoCeutics of Canada have signed an exclusive global collaboration agreement for the Phase III development and commercialisation of dehydroepiandrosterone (DHEA), a new treatment for vaginal atrophy and female sexual dysfunction.